Overview
2seventy bio develops cancer therapies by applying expertise in cancer cell biology, genetics, and the immune response to create treatments that can alter the cancer treatment landscape. Their products are advanced cancer therapies that advance through discovery, research and development, clinical trials, and regulatory approval before being sold or partnered for commercialization. Unlike many competitors, they emphasize rapid translation of science into therapies and pursue collaborations with other pharmaceutical companies to accelerate bringing therapies to patients. The company aims to give people more time to enjoy life by extending survival and improving quality of life for individuals diagnosed with cancer.
Work here?Claim your company
Simplify's take
What believers are saying
- BMS ownership stabilizes funding and absorbs commercialization costs immediately.
- Abecma gained earlier-line FDA approval on April 4, 2024, expanding addressable patients.
- A $242 million 2024 Abecma sales run rate proved the asset still generates cash.
What critics are saying
- Bristol Myers Squibb completed the $287 million acquisition on May 13, 2025; independence ended.
- Nasdaq delisting erased equity upside and eliminated 2seventy bio as a standalone employer brand.
- Abecma faces Carvykti competition and manufacturing pressure, threatening residual franchise value by 2026.
What makes 2seventy Bio unique
- Abecma remains 2seventy bio's only meaningful commercial asset, co-owned with Bristol Myers Squibb.
- The company built rare BCMA CAR-T commercialization expertise in multiple myeloma.
- Cambridge origin and ex-bluebird lineage gave it deep cell-therapy operating talent.
Help us improve and share your feedback! Did you find this helpful?